Behrenbruch Christian - 18 Mar 2026 Form 3 Insider Report for Telix Pharmaceuticals Ltd (TLX)

Reporting relationship
MD & Group CEO, Director
Issuer ticker
TLX
Reported as of
18 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 20:45:57 UTC
Next SEC filing
06 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Genevieve Ryan, on behalf of Dr. Christian Behrenbruch, MD & Group CEO

Key filing fact

Behrenbruch Christian filed Form 3 for Telix Pharmaceuticals Ltd (TLX) on 18 Mar 2026.

Key facts

  • This page summarizes Behrenbruch Christian's Form 3 filing for Telix Pharmaceuticals Ltd (TLX).
  • 0 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 20:45.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002037713 Primary reporting owner

Behrenbruch Christian

Relationship
MD & Group CEO, Director
Address
C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
Signature
/s/ Genevieve Ryan, on behalf of Dr. Christian Behrenbruch, MD & Group CEO
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TLX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
20,675,000
Date
18 Mar 2026
Ownership
Elk River Holdings Pty Ltd
Footnotes
F1
TLX holding

American Depositary Receipts

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
400,000
Date
18 Mar 2026
Ownership
Direct
Footnotes
F2
TLX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
254,006
Date
18 Mar 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TLX holding Derivative

Performance Share Appreciation Rights (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
93,114
Exercise price
$4.95
Footnotes
F3, F4
TLX holding Derivative

Performance Share Appreciation Rights (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
100,223
Exercise price
$6.90
Footnotes
F4, F5
TLX holding Derivative

Share Rights

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
2,595
Exercise price
$0.000000
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.

Footnote F2

Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date.

Footnote F3

The performance share appreciation rights (PSARs) were granted on April 5, 2022 and became vested and exercisable on March 6, 2025.

Footnote F4

Conversion price is reported in Australian Dollars.

Footnote F5

The PSARs were granted on May 30, 2023, and became vested and exercisable on March 12, 2026.

Footnote F6

The share rights were granted on May 21, 2025, and became vested and exercisable on March 5, 2026.

SEC remarks

Ex. 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .